Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 15;131(7):818-821.
doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19.

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation

Amer M Zeidan  1   2 , Maximilian Stahl  1   2 , Xin Hu  2 , Rong Wang  2   3 , Scott F Huntington  1   2 , Nikolai A Podoltsev  1   2 , Steven D Gore  1   2 , Xiaomei Ma  2   3 , Amy J Davidoff  2   4
Affiliations

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation

Amer M Zeidan et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.M.Z. consulted for Celgene, Ariad, Gilead, Incyte, Pfizer, Otsuka, Agios, and Novartis and served as a speaker and received honoraria from Ariad. S.F.H. consulted for Janssen and Celgene and received honoraria from Pharmacyclics. S.D.G. consulted and received research funding from Celgene. A.J.D. received research funding from Celgene. These sources of support were not used for any portion of the current study. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.
See this image and copyright information in PMC

References

    1. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569. - PubMed
    1. Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90(7):969-983. - PubMed
    1. Platzbecker U. Who benefits from allogeneic transplantation for myelodysplastic syndromes? New insights. Hematology Am Soc Hematol Educ Program. 2013;2013:522-528. - PubMed
    1. Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27(5):243-259. - PMC - PubMed
    1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542. - PubMed

Publication types

MeSH terms